The models, alongside the elaborate code to integrate drug-disease pairs of clinical trials to putative common targets through validated data sources, in this proposed framework, can aid various drug research groups in accessing early indicators of success. This optimizes the release of Investigational New Drugs (IND) or New Drug Application (NDA) by narrowing down the number of candidate drugs in scaffolds being considered and limiting the cost, time, and other technical challenges.